blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3986564

EP3986564 - NEW MACROCYCLIC COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  19.04.2024
Database last updated on 06.07.2024
FormerRequest for examination was made
Status updated on  25.03.2022
FormerThe international publication has been made
Status updated on  15.01.2021
Formerunknown
Status updated on  02.07.2020
Most recent event   Tooltip02.07.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2022/17]
Inventor(s)01 / ENGELHARDT, Harald
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
02 / BOESE, Dietrich
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
 [2022/17]
Representative(s)Lutze, Oliver, et al
Boehringer Ingelheim International GmbH
Binger Straße 173
55216 Ingelheim am Rhein / DE
[N/P]
Former [2022/17]Simon, Elke Anna Maria, et al
Boehringer Ingelheim International GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date20734188.423.06.2020
[2022/17]
WO2020EP67451
Priority number, dateEP2019018195224.06.2019         Original published format: EP 19181952
[2022/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020260252
Date:30.12.2020
Language:EN
[2020/53]
Type: A1 Application with search report 
No.:EP3986564
Date:27.04.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 30.12.2020 takes the place of the publication of the European patent application.
[2022/17]
Search report(s)International search report - published on:EP30.12.2020
ClassificationIPC:A61P35/00, C07D487/22, C07D498/22, A61K31/439
[2022/17]
CPC:
A61P35/00 (EP); C07D498/22 (EP,US); A61K45/06 (US);
C07D487/22 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/17]
TitleGerman:NEUE MAKROCYCLISCHE VERBINDUNGEN UND DERIVATE ALS EGFR-INHIBITOREN[2022/17]
English:NEW MACROCYCLIC COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS[2022/17]
French:NOUVEAUX COMPOSÉS MACROCYCLIQUES ET LEURS DÉRIVÉS UTILISÉS EN TANT QU'INHIBITEURS D'EGFR[2022/17]
Entry into regional phase24.01.2022National basic fee paid 
24.01.2022Designation fee(s) paid 
24.01.2022Examination fee paid 
Examination procedure24.01.2022Examination requested  [2022/17]
24.01.2022Date on which the examining division has become responsible
19.08.2022Amendment by applicant (claims and/or description)
23.04.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
30.06.2022Renewal fee patent year 03
30.06.2023Renewal fee patent year 04
01.07.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[AD]WO2013184757  (IRM LLC [US], et al) [AD] 1-27 * examples 17.70, 17.76; claims 1, 3, 21, 22 *;
 [AD]WO2013184766  (IRM LLC [US], et al) [AD] 1-27 * examples 2-15 to 2-18; claims 1, 16 *;
 [ID]WO2014121942  (MERCK PATENT GMBH [DE]) [ID] 1-27* example 18; claims 1, 11 *
by applicantWO03030902
 WO03041708
 WO2004014369
 WO2004014905
 WO2005070420
 WO2005079791
 WO2007133983
 WO2012018668
 WO2013184757
 WO2013184766
 WO2014036016
 WO2014081718
 WO2014121942
 WO2014210354
 WO2015143148
 WO2015143161
 WO2016176473
 WO2016185333
 WO2017004383
 WO2017019896
 WO2017049068
 WO2017049069
    - BERSANELLI, B. et al., "L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC", Journal of Thoracic Oncology, (20160000), vol. 11, pages e121 - e123
    - BLAKELY, C.M., "Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance", Cancer Discov., (20120000), vol. 2, pages 872 - 875
    - BRYAN, M. C., "Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR", ACS Med. Chem. Lett., (20160000), vol. 7, pages 100 - 104
    - CHAN, B. K. et al., "Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor", J. Med. Chem. 2016, (20160000), vol. 59, doi:10.1021/acs.jmedchem.6b00995, pages 9080 - 9093, XP055497250

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.6b00995
    - CHEN, K. et al., "Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC", Journal of Thoracic Oncology, (20170000), vol. 12, pages e65 - e68
    - CHEN, L., "Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells", Eu. J. Med. Chem., (20170000), vol. 138, doi:10.1016/j.ejmech.2017.06.023, pages 689 - 697, XP085163688

DOI:   http://dx.doi.org/10.1016/j.ejmech.2017.06.023
    - CROSS, D.A.E. et al., "AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer", Cancer Discovery, (20140900), vol. 4, no. 9, pages 1046 - 61
    - ENGEL, J., "Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR", Angew. Chem. Int. Ed., (20160000), vol. 55, pages 10909 - 10912
    - GUNTHER, M., "Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site", J. Med. Chem., (20170000), vol. 60, pages 5613 - 5637
    - HANAN, E. J. et al., "Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation", J. Med. Chem., (20140000), vol. 57, doi:10.1021/jm501578n, pages 10176 - 10191, XP055201841

DOI:   http://dx.doi.org/10.1021/jm501578n
    - HEALD, R. et al., "Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study", J. Med. Chem., (20150000), vol. 58, pages 8877 - 8895
    - JANNE, P.A et al., "AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer", N. Engl. J. Med., (20150000), vol. 372, doi:10.1056/NEJMoa1411817, pages 1689 - 1699, XP009516238

DOI:   http://dx.doi.org/10.1056/NEJMoa1411817
    - JIA, Y. et al., "EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor", Cancer Research, (20160000), vol. 76, pages 1591 - 1602, XP009191015
    - JUCHUM, M., "Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping", J. Med. Chem., (20170000), vol. 60, doi:10.1021/acs.jmedchem.7b00178, pages 4636 - 4656, XP055475112

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.7b00178
    - KOBAYASHI, S. et al., "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib", N. Engl. J. Med., (20050000), vol. 352, pages 786 - 792, XP002395764
    - KONDURI, K. et al., "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer", Cancer Discovery, (20160600), vol. 6, no. 6, pages 601 - 11
    - LELAIS, G. et al., "Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent", J. Med. Chem., (20160000), vol. 59, doi:10.1021/acs.jmedchem.5b01985, pages 6671 - 6689, XP055369965

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.5b01985
    - MIDHA, A., "EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapll", Am J Cancer Res., (20150000), vol. 5, no. 9, pages 2892 - 2911
    - MITSUDOMI, T. et al., "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial", Lancet Oncol, (20100000), vol. 11, doi:10.1016/S1470-2045(09)70364-X, pages 121 - 128, XP026884314

DOI:   http://dx.doi.org/10.1016/S1470-2045(09)70364-X
    - MOK, T.S. et al., "Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer", N. Engl. J. Med., (20160000), vol. 367, pages 629 - 640
    - ORTIZ-CUARAN, S. et al., "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors", Clin. Cancer Res., (20160000), vol. 22, pages 4837 - 4847
    - J Clin Oncol, (20170000), vol. 35
    - PARK, H., "Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design", Angew. Chem. Int. Ed., (20170000), vol. 56, pages 7634 - 7638
    - PARK, K. et al., "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial", Lancet Oncol., (20160000), vol. 17, pages 577 - 589
    - PATEL, H. M., "Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle", Biorg. Med. Chem., (20170000), vol. 25, doi:10.1016/j.bmc.2017.03.039, pages 2713 - 2723, XP029978684

DOI:   http://dx.doi.org/10.1016/j.bmc.2017.03.039
    - SONG, H.N. et al., "Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer", J. Thorac. Oncol., (20160000), vol. 11, pages e45 - 47
    - THRESS, K.S. et al., "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M", Nat. Med., (20150000), vol. 21, doi:10.1038/nm.3854, pages 560 - 562, XP055598374

DOI:   http://dx.doi.org/10.1038/nm.3854
    - WANG, S. et al., "Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer", J Hematol Oncol., (20160412), vol. 9, page 34
    - YU, H.A. et al., "Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain", JAMA Oncol., (20150000), vol. 1, doi:10.1001/jamaoncol.2015.1066, pages 982 - 984, XP055612845

DOI:   http://dx.doi.org/10.1001/jamaoncol.2015.1066
    - ZHANG, Y., "Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and a-glucosidase", Bioorg. Med. Chem. Lett., (20170000), vol. 27, doi:10.1016/j.bmcl.2017.08.035, pages 4309 - 4313, XP085185731

DOI:   http://dx.doi.org/10.1016/j.bmcl.2017.08.035
    - ZHOU, C. et al., "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", Lancet Oncol., (20110000), vol. 12, doi:10.1016/S1470-2045(11)70184-X, pages 735 - 742, XP055073569

DOI:   http://dx.doi.org/10.1016/S1470-2045(11)70184-X
    - Helvetica Chimica Acta, (20130000), vol. 96, pages 2160 - 2172
    - Organic Preparations and Procedures Int., (20040000), vol. 36, pages 76 - 81
    - J. Org. Chem., (20070000), vol. 72, pages 4067 - 4072
    - Org. Lett., (20110000), vol. 13, pages 252 - 255
    - J. Org. Chem., (20040000), vol. 69, pages 7779 - 7782
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.